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Purpose: Non-small-cell lung cancer (NSCLC) has a large worldwide prevalence with a 
high mortality rate. Chemotherapy has offered modest improvements in survival over the 
past two decades. Immune checkpoint modulation with programmed death-1 (PD-1) 
or programmed death-ligand 1 (PD-L1) inhibition has shown the promise of changing 
the future landscape of cancer therapy. This update reviews recent advances in the 
treatment of NSCLC with immune checkpoint modulation.
Methods: Publications and proceedings were identified from searching PubMed and 
proceedings from the annual meetings of the American Society of Clinical Oncology, 
European Society for Medical Oncology, and European Lung Cancer Conference.
Results: Atezolizumab, nivolumab, and pembrolizumab increase overall survival in 
second-line treatment of Stage III/IV squamous and non-squamous NSCLC when 
compared to docetaxel. Pembrolizumab increases progression-free survival in the 
first-line treatment of Stage IV NSCLC with 50% PD-L1 expression when compared to 
platinum-based chemotherapy. Combination therapy with chemotherapy and cytotoxic 
T-lymphocyte-associated protein 4 (CTLA-4) inhibitors has shown promise in early trials.
Conclusion: Immune checkpoint modulation produces durable responses and overall 
survival benefits with less toxicity compared to conventional chemotherapy. Future inves-
tigations are combining PD-1/L1 inhibition with chemotherapy, targeted therapy, or other 
immuno-oncology agents in an effort to further improve efficacy.
Keywords: non-small-cell lung cancer, immuno-oncology, programmed death-1, programmed death-ligand 1, 
CTLA-4
iNTRODUCTiON
More than 100 years of research in the field of cancer immunotherapy has produced several modali-
ties capable of producing clinical response (1). Most notably, immune checkpoint modulation has 
shown the promise of changing the future landscape of cancer therapy through its durable clinical 
responses (2–4) and safety profiles of some agents that are either milder and/or more manageable 
compared to traditional anti-neoplastic therapies (5). Cytotoxic T-lymphocyte-associated protein 4 
(CTLA-4), the first immune checkpoint receptor to be clinically targeted, is exclusively expressed 
on the surface of CD4+ and CD8+ T cells in lymphatic tissue and is involved in T-cell regulation, 
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proliferation, and tolerance (6). The repertoire of immune modu-
lation was expanded with the advent of programmed death-1 
(PD-1) immune checkpoint inhibitor antibodies, which restores 
T-cell effector function and augments the host anti-tumor 
response by blocking the binding of either programmed death-
ligand 1 (PD-L1) and/or PD-L2 to PD-1 receptors (7).
Following the clinical success of treating melanoma with 
immune checkpoint modulation (8), trialists have expanded the 
application of checkpoint inhibitors to multiple tumor types, 
including lung cancer (9). Globally, 1.8 million new diagnoses 
of lung cancer occurred in 2012; with a mortality rate of nearly 
90%, lung cancer is the first and second cause of cancer mortality 
in men and women, respectively (10). Eighty-five percent of lung 
cancers are non-small-cell lung cancer (NSCLC), further divided 
into non-squamous (70%) and squamous (30%) histologic sub-
types (11). Metastatic disease is present in 50% of new NSCLC 
diagnoses (12, 13), which harbors an untreated median overall 
survival (mOS) of 4.0 months (14) and a metastatic 5-year survival 
rate ranging from 2 to 9% (15). Although mortality has improved 
with the use of targeted drugs for driver mutations (16–20), few 
patients harbor these mutations and resistance to targeted treat-
ment frequently occurs (21). Currently, NSCLC has numerous 
checkpoint inhibitors being evaluated for clinical efficacy (22). The 
possible treatment of NSCLC is being further enriched through 
the addition of other immune modulation targets and combina-
tion therapy. At present, the Food and Drug Administration has 
approved three immuno-oncology agents for the treatment of 
NSCLC: atezolizumab, nivolumab, and pembrolizumab in the 
relapsed, refractory setting as well as pembrolizumab for the first- 
line treatment of metastatic NSCLC with a tumor proportion 
score (TPS) ≥50%. This update will offer guidance into the cur-
rent application and pending developments for treatment NSCLC 
with immune modulating pharmacotherapy.
MeTHODS
Current studies investigating the use of immune checkpoint mod-
ulation in NSCLC were reviewed by searching PubMed (January 
1, 2015 to December 30, 2016) using the following search terms: 
non-small-cell lung cancer and immune checkpoint modulation 
(or aliases). Any proceedings from the American Society of Clini- 
cal Oncology (ASCO) (2015–2016), European Society for Medical 
Oncology (ESMO) (2015–2016), and European Lung Cancer 
Conference (ELCC) (2015–2016) annual meetings involving both 
NSCLC and immune checkpoint modulation were reviewed. 
Table 1 summarizes the search results and each trial’s pertinent 
characteristics.
ReSULTS
Third Line
CheckMate 063 is a Phase 2, open-label, global, multicenter, 
single-arm trial investigating the use of nivolumab, a fully human 
immunoglobulin G4 (IgG4) monoclonal antibody that selectively 
inhibits the PD-1 receptor, dosed 3 mg/kg every 2 weeks (n = 117) 
in patients with either Stage IIIb/IV squamous NSCLC who have 
received prior platinum-doublet and one additional systemic 
treatment. Treatment with nivolumab continued until progres-
sive disease (PD) or an unacceptable treatment-related adverse 
event (TRAE), although treatment beyond PD was permitted 
as per protocol. The primary endpoint was overall response rate 
(ORR) by independent radiology review (per RECIST v1.1). The 
ORR was 14.5% (95% CI 9–22). mOS was 8.2 months (95% CI 
6.1–10.9), with 12-month OS and 18-month OS rates of 39% 
(95% CI 30–48) and 27% (95% CI 19–35), respectively. TRAE 
of any Grade occurred in 75% of patients, Grade 3–4 TRAEs 
occurred in 17%, TRAE lead to nivolumab discontinuation in 12%, 
and death occurred in two patients secondary to nivolumab, 
although these patients had multiple comorbidities in the set-
ting of PD (23, 24). These results are similar to those obtained 
from two smaller Japanese trials (25). To put this in historical 
perspective, a retrospective analysis looking at third-line treat-
ment (58% received cytotoxic chemotherapy, 42% EGFR received 
tyrosine kinase inhibitors) in patients who had not received any 
immunotherapy found a 6.5-month mOS, 3.4-month median 
progression-free survival (mPFS), and 8% ORR (26).
Second Line
CheckMate 017 is a Phase 3, global, multicenter, open-label, 1:1 
randomized trial comparing nivolumab 3 mg/kg every 2 weeks 
(n = 135) or docetaxel 75 mg/m2 every 3 weeks (n = 137) in patients 
with Stage IIIb/IV squamous NSCLC histology that recurred or 
progressed following prior platinum-doublet therapy. Treatment 
continued until PD or unacceptable toxicity, and treatment 
beyond PD was allowed. The primary endpoint was OS. Nivolumab 
had an mOS of 9.2 months (95% CI 7.33–12.62) versus docetaxel 
with 6.0 months (95% CI 5.29–7.39). The risk of death was 41% 
lower with nivolumab versus docetaxel [hazard ratio (HR) 0.59, 
95% CI 0.44–0.79; p < 0.001]. The ORR with nivolumab was 20 
versus 9% with docetaxel. PD-L1 expression stratified to 1, 5, and 
10% was not predictive of benefit. Nivolumab had less TRAEs 
compared to docetaxel: TRAEs of any grade were reported in 
59 versus 87% of patients, respectively, and Grades 3–4 TRAEs 
were reported in 8 versus 56% of patients, respectively. Study 
discontinuation due to a TRAE was reported for 5% of nivolumab 
versus 10% of docetaxel patients. No treatment-related deaths 
occurred with nivolumab and two deaths occurred in patients 
receiving docetaxel that were determined to be treatment-related 
(27). This efficacy is similar to the single-arm CheckMate 063 
results (23). OS was updated at the ASCO 2016 Annual Meeting: 
the 1- and 2-year OS for nivolumab was 42 and 23%, respectively, 
in comparison to 24 and 8% for docetaxel (28).
CheckMate 057 is a Phase 3, global, multicenter, open-label, 
1:1 randomized trial comparing nivolumab 3 mg/kg every 2 weeks 
(n =  292) to docetaxel 75  mg/m2 every 3  weeks (n =  290) in 
patients with Stage III/IV non-squamous NSCLC that recurred 
or progressed on platinum-doublet chemotherapy. Treatment 
continued until PD or discontinuation due to toxicity; treatment 
beyond PD was permitted per protocol. This study met its pri-
mary endpoint of OS, with nivolumab mOS 12.2 months versus 
docetaxel 9.4 months, yielding a 27% reduction in risk of death 
(HR 0.73; p  =  0.002) and improved ORR (19 versus 12%; 
p = 0.02). Using pre-defined PD-L1 expression levels of ≥1, ≥5, 
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TAbLe 1 | Summary of advanced or metastatic non-small-cell lung cancer immuno-oncology trials.
Type of 
treatment
Trial name Trial 
phase
Stage Histology Programmed 
death-ligand 
1 (PD-L1) 
tumor 
expression 
level
Study arm (n) Comparative 
arm (n)
Primary endpoint 
(study versus 
comparator)a
Secondary 
endpoint(s) (study 
versus comparator, 
when appropriate)a,b
TRAes 
(study versus 
comparator)a
Death 
from 
study drug 
(patients)a
Reference
Monotherapy 
anti-PD-1/L1
Third line CheckMate 
063
2 IIIb/IV Squamous ≥1, ≥5, ≥10, 
and ≥5% for 
analysis
Nivolumab 
3 mg/kg 
every 2 weeks 
(n = 117)
N/A ORR: 14.5% (95% 
CI 8.7–22.2%)
mOS: 8.2 months 
(95% CI 6.1–10.9)
Grade 3–4: 
17%
2 (23)
median progression-
free survival (mPFS): 
1.9 months (95% CI 
1.8–3.2)
Second 
line
CheckMate 
017
3 IIIb/IV Squamous ≥1, ≥5, and 
≥10%
Nivolumab 
3 mg/kg 
every 2 weeks 
(n = 135)
Docetaxel 
75 mg/m2 
every 3 weeks 
(n = 137)
mOS: 9.2 versus 
6.0 months [hazard 
ratio (HR) 0.59; 
95% CI 0.44–0.79; 
p < 0.001]
mPFS: 3.5 versus 
2.8 months (HR 0.62; 
95% CI 0.47–0.81; 
p < 0.001)
Grade 3–4: 8 
versus 56% 
0 (26)
ORR: 20 versus 9% 
(p = 0.008)
CheckMate 
057
3 IIIb/IV Non-
squamous
≥1, ≥5, and 
≥10%
Nivolumab 
3 mg/kg 
every 2 weeks 
(n = 292)
Docetaxel 
75 mg/m2 
every 3 weeks 
(n = 290)
mOS: 12.2 versus 
9.4 months (HR 
0.73; 95% CI 0.59–
0.89; p = 0.002)
mPFS: 2.3 versus 
4.2 months (HR 0.92; 
95% CI 0.77–1.11; 
p = 0.39)
Grade 3–4: 10 
versus 54% 
0 (27)
ORR: 19 versus 12% 
(p = 0.02)
Keynote 010 2 and 
3
IIIb/IV Squamous 
and non-
squamous
≥1 and ≥50% Pembrolizumab 
2 mg/kg 
every 3 weeks 
(n = 345)
Docetaxel 
75 mg/m2 
every 3 weeks 
(n = 343)
mOS (PD-L1 
expression ≥1%; 
pembro 2 mg/
kg): 10.4 versus 
8.5 months (HR 
0.71; 95% CI 0.58–
0.88; p = 0.0008)
ORR (PD-L1 
expression ≥1%; 
pembro 2 mg/
kg): 18 versus 9% 
(p = 0.0005)
Grade 3–5: 
13% (pembro 
2 mg/kg) and 
16% (pembro 
10 mg/kg) 
versus 35%
3 (pembro 
2 mg/
kg) and 3 
(pembro 
10 mg/kg)
(29)
Pembrolizumab 
10 mg/kg 
every 3 weeks 
(n = 346)
mOS (PD-L1 
expression ≥1%; 
pembro 10 mg/
kg): 12.7 versus 
8.2 months (HR 
0.61; 0.49–0.75; 
p < 0.0001)
ORR (PD-L1 
expression ≥1%; 
pembro 10 mg/
kg): 18 versus 9% 
(p = 0.0002)
mPFS (PD-L1 
expression ≥1%; 
pembro 2 mg/
kg): 3.9 versus 
4.0 months (HR 
0.88; 95% CI 0.74–
1.05; p = 0.07)
ORR (PD-L1 
expression ≥50%; 
pembro 2 mg/
kg): 30 versus 8% 
(p < 0.0001)
(Continued )
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Type of 
treatment
Trial name Trial 
phase
Stage Histology Programmed 
death-ligand 
1 (PD-L1) 
tumor 
expression 
level
Study arm (n) Comparative 
arm (n)
Primary endpoint 
(study versus 
comparator)a
Secondary 
endpoint(s) (study 
versus comparator, 
when appropriate)a,b
TRAes 
(study versus 
comparator)a
Death 
from 
study drug 
(patients)a
Reference
mPFS (PD-L1 
expression ≥1%; 
pembro 10 mg/
kg): 4.0 versus 
4.0 months (HR 
0.79; 95% CI 0.66–
0.94; p = 0.004)
ORR (PD-L1 
expression ≥ 50%; 
pembro 10 mg/
kg): 29% vs 8% 
(p < 0.0001)
mOS (PD-L1 
expression ≥50%; 
pembro 2 mg/
kg): 14.9 versus 
8.2 months (HR 
0.54; 95% CI 0.38–
0.77; p = 0.0002)
mOS (PD-L1 
expression ≥50%; 
pembro 10 mg/
kg): 17.3 versus 
8.2 months (HR 
0.50; 95% CI 0.36–
0.70; p < 0.0001)
mPFS (PD-L1 
expression ≥50%; 
pembro 2 mg/
kg): 5.0 versus 
4.1 months (HR 
0.59; 95% CI 0.44–
0.78; p = 0.0001)
mPFS (PD-L1 
expression ≥50%; 
pembro 10 mg/
kg): 5.2 versus 
4.1 months (HR 
0.59; 95% CI 0.45–
0.78; p < 0.0001)
OAK 3 IIIb/IV Squamous 
and non-
squamous
TC/IC 0 = <1% 
TC/IC; TC/
IC 1 = ≥1% 
TC/IC; TC/
IC 2 = ≥5% 
TC/IC; TC/
IC 3 = ≥50% 
TC/≥10% IC
Atezolizumab 
1,200 mg 
(n = 425) every 
3 weeks
Docetaxel 
75 mg/m2 
every 3 weeks 
(n = 425)
mOS: 13.8 versus 
9.6 months (HR 
0.73; 95% CI 0.62–
0.87; p = 0.0003)
mPFS: 4.0 versus 
2.8 months (HR 0.95; 
95% CI 0.82–1.10; 
p = 0.493)
Grade 3–4: 15 
versus 43%
0 (31)
TAbLe 1 | Continued
(Continued )
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Type of 
treatment
Trial name Trial 
phase
Stage Histology Programmed 
death-ligand 
1 (PD-L1) 
tumor 
expression 
level
Study arm (n) Comparative 
arm (n)
Primary endpoint 
(study versus 
comparator)a
Secondary 
endpoint(s) (study 
versus comparator, 
when appropriate)a,b
TRAes 
(study versus 
comparator)a
Death 
from 
study drug 
(patients)a
Reference
 mOS (PD-L1 
expression ≥1%): 
15.7 versus 
10.3 months (HR 
0.74; 95% CI 0.58–
0.93; p = 0.0102)
First line Keynote 024 3 IV Squamous 
and non-
squamous
≥50% Pembrolizumab 
200 mg every 
3 weeks 
(n = 154)
Investigator’s 
choice of 
five different 
platinum-
based 
chemotherapy 
regimens 
(n = 150)
mPFS (PD-L1 
expression ≥50%): 
10.3 versus 
6.0 months (HR 
0.50; 95% CI 0.37–
0.68; p < 0.001)
mOS (yet to be 
reached). Six-month 
survival (PD-L1 
expression ≥5%): 
80.2% versus 72.4% 
(HR 0.60; 95% CI 
0.41–0.89; p = 0.005) 
Grade 3–5: 
26.6 versus 
53.3%
0 (32)
ORR (PD-L1 
expression ≥5%): 44.8 
versus 42% (p value 
not reported)
CheckMate 
026
3 IV or 
recurrent
Squamous 
and non-
squamous
≥1 and ≥5% Nivolumab 
3 mg/kg 
every 2 weeks 
(n = 271)
Investigator’s 
choice of 
platinum-
based doublet 
chemotherapy 
(n = 270)
mPFS (PD-L1 
expression 
≥5%): 4.2 versus 
5.9 months (HR 
1.15, 95% CI 0.91–
1.45; p = 0.25)
mPFS: not reported Grade 3–4: 18 
versus 51%
Not stated (33)
 mOS: 14.4 versus 
13.2 months 
(HR = 1.02; 95% CI: 
0.80–1.30) (p value 
not stated)
ORR: not reported
Combination 
chemotherapy 
and anti-PD-1 
therapy
CheckMate 
012
1 IIIb/IV Squamous 
and non-
squamous
<1 and ≥1% Squamous: 
nivolumab 
10 mg/kg every 
3 weeks plus 
gemcitabine-
cisplatin (n = 12)
N/A Tolerability: 21% 
discontinuation 
from TRAE; TRAE 
(grade 3–4): 45%
ORR (nivo 10 mg/kg 
plus gem-cis): 33%
Grade 3–4: 
45%
0 (35)
Non-squamous: 
nivolumab 
10 mg/kg every 
3 weeks plus 
pemetrexed-
cisplatin (n = 15)
ORR (nivo 10 mg/kg 
plus pem-cis): 47%
TAbLe 1 | Continued
(Continued )
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Type of 
treatment
Trial name Trial 
phase
Stage Histology Programmed 
death-ligand 
1 (PD-L1) 
tumor 
expression 
level
Study arm (n) Comparative 
arm (n)
Primary endpoint 
(study versus 
comparator)a
Secondary 
endpoint(s) (study 
versus comparator, 
when appropriate)a,b
TRAes 
(study versus 
comparator)a
Death 
from 
study drug 
(patients)a
Reference
All histologies: 
nivolumab 5 
or 10 mg/kg 
every 3 weeks 
plus paclitaxel-
carboplatin 
(n = 14 and 
n = 15, 
respectively)
ORR (nivo 10 mg/kg 
plus pacli-carbo): 47%
ORR (nivo 5 mg/kg 
plus pacli-carbo): 43%
progression-free 
survival (PFS) 
(24 weeks; nivo 
10 mg/kg plus gem-
cis): 51%
PFS (24 weeks; nivo 
10 mg/kg plus pem-
cis): 71%
PFS (24 weeks; nivo 
10 mg/kg plus pacli-
carbo): 38%
PFS (24 weeks; nivo 
5 mg/kg plus pacli-
carbo): 51%
Keynote 021 1 and 
2
IIIb/IV Non-
squamous
<1 and ≥1% Pembrolizumab 
200 mg every 
3 weeks plus 
pemetrexed-
carboplatin 
(n = 60)
Pemetrexed-
carboplatin 
(n = 63)
ORR: 55 versus 
29% (95% 
CI 9–42%; 
p = 0.0016)
mPFS: 13.0 versus 
8.9 months (HR 0.53; 
95% CI 0.31–0.91; 
p = 0.010)
Grade 3–5: 39 
versus 26%
1 (36)
OS (12 months): 75 
versus 72%
 
ORR (<1versus ≥1% 
in pembro arm): 57 
versus 54% 
ORR (PD-L1 1–49% in 
pembro arm): 26%
ORR (PD-L1 ≥50% in 
pembro arm): 80% 
TAbLe 1 | Continued
(Continued )
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Type of 
treatment
Trial name Trial 
phase
Stage Histology Programmed 
death-ligand 
1 (PD-L1) 
tumor 
expression 
level
Study arm (n) Comparative 
arm (n)
Primary endpoint 
(study versus 
comparator)a
Secondary 
endpoint(s) (study 
versus comparator, 
when appropriate)a,b
TRAes 
(study versus 
comparator)a
Death 
from 
study drug 
(patients)a
Reference
Combination 
anti-PD-1/L1 
therapy and 
anti-CTLA-4 
therapy
Keynote 021 1 and 
2
IIIb/IV Non-
squamous
<1 and ≥1% Maximum dose: 
Pembrolizumab 
10 mg/kg every 
3 weeks plus 
ipilimumab 1 or 
3 mg/kg every 
3 weeks (only 
four cycles)
N/A Dose-limiting 
toxicities: none
None defined All grade: 
10 patients 
(66.7%) 
0 (37)
Final dose 
selected: 
pembrolizumab 
2 mg/kg and 
ipilimumab 
1 mg/kg
 TRAE (all grades): 
10 patients (66.7%) 
CheckMate 
012
1 IIIb/IV Squamous 
and non-
squamous
<1 and ≥1% Nivolumab 
1 mg/kg every 
2 weeks plus 
ipilimumab 
1 mg/kg every 
6 weeks (data 
not reported in 
publication)
N/A TRAE (grade 3–4; 
ipi every 6 weeks): 
33% 
ORR (ipi every 
6 weeks): 38% (95% 
CI 23–55)
TRAE (grade 
3–4; ipi every 
6 weeks): 33% 
0 (39)
Nivolumab 
3 mg/kg every 
2 weeks plus 
ipilimumab 
1 mg/kg every 
12 weeks 
(n = 38)
 TRAE (grade 3–4; 
ipi every 12 weeks): 
37% 
ORR (ipi every 
12 weeks): 47% (95% 
CI 31–64)
TRAE (grade 
3–4; ipi every 
12 weeks): 
37% 
Nivolumab 
3 mg/kg every 
2 weeks plus 
ipilimumab 
1 mg/kg 
every 6 weeks 
(n = 39)
 PFS (24 weeks; ipi 
every 6 weeks): 65% 
(95% CI 42–81)
PFS (24 weeks; ipi 
every 12 weeks): 80% 
(95% CI 55–92)
TAbLe 1 | Continued
(Continued )
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and ≥10% from archival tumors, nivolumab showed improved 
efficacy across all endpoints. PD-L1 expression predicted the ben-
efit of nivolumab, even at the lowest expression level of 1%. mOS 
approximately doubled with nivolumab versus docetaxel across 
PD-L1 expression levels; conversely, survival was equivocal with 
negative PD-L1 expression. Grades 3–4 TRAEs occurred in 10 
and 54% of nivolumab and docetaxel patients, respectively. There 
were no nivolumab-related deaths, whereas docetaxel led to one 
death. Subsequent systemic therapy was given to 42.1 and 49.7% 
of nivolumab and docetaxel patients, respectively (29). Investiga- 
tors at the ASCO 2016 Annual Meeting presented an update to the 
1- and 2-year OS for nivolumab noting 51 and 29%, respectively, 
in comparison to 39 and 16% for docetaxel (28).
Keynote 010 is Phase 2/3, global, multicenter, open-label, 
randomized, controlled study to evaluate the safety and efficacy 
of pembrolizumab, a humanized monoclonal IgG4 antibody 
that selectively inhibits the PD-1 receptor. Patients with NSCLC 
and tumor cell PD-L1 expression ≥1% who progressed after 
 platinum-doublet chemotherapy were randomized 1:1:1 to receive 
pembrolizumab 2  mg/kg (n =  345), pembrolizumab 10  mg/kg 
(n = 346), or docetaxel 75 mg/m2 (n = 343) every 3 weeks; no 
crossover was allowed. Treatment was continued for 24 months, 
or until PD or discontinuation due to toxicity; treatment 
beyond PD was allowed. The primary endpoints were OS and 
 progression-free survival (PFS) (by independent radiology review 
as per RECIST v1.1) in both all patients and those with PD-L1 
expression ≥50% of tumor cells (TCs) from either archival or 
new biopsies. Compared to docetaxel, risk of death was decreased 
with both pembrolizumab 2 mg/kg (HR 0.71, 95% CI 0.58–0.88; 
p = 0.0008) and pembrolizumab 10 mg/kg (HR 0.61, 0.49–0.75; 
p <  0.0001). Patients with PD-L1 expression ≥50% had better 
mOS with pembrolizumab 2 mg/kg (14.9 versus 8.2 months; HR 
0.54, 95% CI 0.38–0.77; p = 0.0002) and pembrolizumab 10 mg/kg 
(17.3 versus 8.2 months; HR 0.50, 95% CI 0.36–0.70; p < 0.0001) 
versus docetaxel. Grades 3–5 TRAEs were less common with 
pembrolizumab versus docetaxel: 13, 16, and 35% for those treated 
with pembrolizumab 2 mg/kg, pembrolizumab 10 mg/kg, and doc-
etaxel, respectively (30). Investigators at the ASCO 2016 Annual 
Meeting presented an update on the patients with 1–49% PD-L1 
expression: OS was longer for both pembrolizumab 2  mg/kg 
(9.4  months) versus docetaxel (8.6  months) (HR 0.79, 95% CI 
0.61–1.04) and pembrolizumab 10 mg/kg (10.8 months) versus 
docetaxel (8.6 months) (HR 0.71, 0.53–0.94) (31).
The OAK study is a Phase 3, global, multicenter, open-label, 
randomized, controlled study to evaluate the efficacy and safety 
of atezolizumab, a humanized IgG1-kappa monoclonal antibody 
that binds PD-L1 and inhibits PD-L1/PD-1 and PD-L1/B7.1 
interactions (32). Patients with Stage IIIb/IV or recurrent non-
squamous NSCLC following failure of platinum-based treatment 
were randomized 1:1 to receive either fixed dose atezolizumab 
1,200  mg (n =  425) or docetaxel 75  mg/m2 (n =  425) every 
3  weeks; no crossover was allowed. Treatment continued until 
disease progression or unacceptable toxicity occurred; treatment 
beyond PD was allowed. The study had co-primary endpoints of 
OS in the full study population, in addition to OS in patients with 
PD-L1 expression ≥1% of TCs or tumor-infiltrating immune cells 
(IC) by the Ventana SP142 assay. mOS was significantly longer Ty
p
e 
o
f 
tr
ea
tm
en
t
Tr
ia
l n
am
e
Tr
ia
l 
p
ha
se
S
ta
g
e
H
is
to
lo
g
y
P
ro
g
ra
m
m
ed
 
d
ea
th
-l
ig
an
d
 
1 
(P
D
-L
1)
 
tu
m
o
r 
ex
p
re
ss
io
n 
le
ve
l
S
tu
d
y 
ar
m
 (n
)
C
o
m
p
ar
at
iv
e 
ar
m
 (n
)
P
ri
m
ar
y 
en
d
p
o
in
t 
(s
tu
d
y 
ve
rs
us
 
co
m
p
ar
at
o
r)
a
S
ec
o
nd
ar
y 
en
d
p
o
in
t(
s)
 (s
tu
d
y 
ve
rs
us
 c
o
m
p
ar
at
o
r, 
w
he
n 
ap
p
ro
p
ri
at
e)
a,
b
T
R
A
e
s 
(s
tu
d
y 
ve
rs
us
 
co
m
p
ar
at
o
r)
a
D
ea
th
 
fr
o
m
 
st
ud
y 
d
ru
g
 
(p
at
ie
nt
s)
a
R
ef
er
en
ce
D
41
90
C
00
00
6
1b
III
/IV
S
qu
am
ou
s 
an
d 
no
n-
sq
ua
m
ou
s
U
nk
no
w
n,
 
0,
 <
25
, a
nd
 
≥2
5%
M
ax
im
um
 d
os
e:
 
du
rv
al
um
ab
 
20
 m
g/
kg
 w
ith
 
tr
em
el
im
um
ab
 
3 
m
g/
kg
N
/A
S
er
io
us
 a
dv
er
se
 
ev
en
t (
“s
er
io
us
” 
no
t 
fo
rm
al
ly
 d
efi
ne
d)
: 
37
%
O
R
R
 (d
ur
va
lu
m
ab
 
10
–2
0 
m
g/
kg
 e
ve
ry
 
2 
w
ee
ks
 o
r 
4 
w
ee
ks
 
pl
us
 tr
em
el
im
um
ab
 
1 
m
g/
kg
): 
23
%
 (9
5%
 
C
I 9
–4
4)
S
er
io
us
 
ad
ve
rs
e 
ev
en
t 
(“
se
rio
us
” 
no
t f
or
m
al
ly
 
de
fin
ed
): 
37
%
3
( 4
0)
Fi
na
l d
os
e 
se
le
ct
ed
: 
du
rv
al
um
ab
 
10
 m
g/
kg
 a
nd
 
tr
em
el
im
um
ab
 
1 
m
g/
kg
, b
ot
h 
ev
er
y 
4 
w
ee
ks
 
(n
 =
 1
02
)
m
O
S
, m
ed
ia
n 
ov
er
al
l s
ur
vi
va
l; 
m
P
FS
, m
ed
ia
n 
pr
og
re
ss
io
n-
fre
e 
su
rv
iv
al
; n
, n
um
be
r 
of
 p
at
ie
nt
s;
 O
R
R
, o
ve
ra
ll 
re
sp
on
se
 r
at
e;
 T
R
A
E,
 tr
ea
tm
en
t-
re
la
te
d 
ad
ve
rs
e 
ev
en
t.
a R
es
ul
ts
 a
re
 fo
r 
al
l s
tu
di
ed
 p
at
ie
nt
s,
 u
nl
es
s 
ot
he
rw
is
e 
st
at
ed
.
b O
nl
y 
se
le
ct
ed
 s
ec
on
da
ry
 e
nd
po
in
ts
 r
ep
or
te
d 
in
 T
ab
le
 1
TA
b
Le
 1
 | 
C
o
nt
in
ue
d
9Iafolla and Juergens Update in Immuno-Oncology in Metastatic NSCLC
Frontiers in Oncology | www.frontiersin.org April 2017 | Volume 7 | Article 67
for atezolizumab versus docetaxel (13.8 versus 9.6 months, strati-
fied HR 0.73, 95% CI 0.62–0.87; p = 0.0003), and had 12- and 
18-month OS of 55 versus 41% and 40 versus 27%, respectively. OS 
was significant regardless of presence of PD-L1 expression: 55% 
of patients had PD-L1 expression ≥1% and had OS of 15.7 months 
versus docetaxel 10.3 months (stratified HR 0.74, 95% CI 0.58–
0.93; p = 0.0102); 45% of patients had no TC or IC with PD-L1 
expression with a respective OS of 12.6 months versus docetaxel 
8.9 months (HR 0.75, 95% CI 0.59–0.96; p = 0.0215); and 16% 
of patients had high TC (≥50%) or IC (≥10%) PD-L1 expres-
sion and had OS of 20.5  months versus docetaxel 8.9  months 
(HR 0.41, 95% CI 0.27–0.64; p < 0.0001). Further, OS was also 
significant regardless of NSCLC histology: non-squamous 
NSCLC had OS of 15.6  months versus docetaxel 11.2  months 
(HR 0.73, 95% CI 0.60–0.89; p = 0.0015); squamous NSCLC had 
OS of 8.9 months versus docetaxel 7.7 months (HR 0.73, 95% CI 
0.54–0.98; p = 0.0383). Five percent of the atezolizumab group 
went on to receive subsequent immunotherapy versus 17% in the 
docetaxel group. Atezolizumab was well tolerated: only 15% of 
patients treated with atezolizumab had Grades 3–4 adverse events 
compared to 43% of the patients treated with docetaxel (33).
First Line
Keynote 024 is Phase 3, global, multicenter, open-label, 1:1 ran- 
domized trial comparing fixed dose pembrolizumab 200  mg 
every 3 weeks (n = 154) to the investigator’s choice of five differ-
ent platinum-based chemotherapy regimens (n = 150) in patients 
with both squamous and non-squamous Stage IV NSCLC who 
have not received prior systemic therapy for their metastatic dis-
ease and have PD-L1 expression on ≥50% of TCs. Treatment with 
pembrolizumab and platinum-based chemotherapy continued 
for a total of 35 cycles (~2 years) and 4–6 cycles, respectively, or 
until the patient had radiologic disease progression or unaccep-
table toxicity. Pemetrexed maintenance was allowed for patients 
with non-squamous histology. Crossover from chemotherapy to 
pembrolizumab was allowed if PD occurred. The primary end 
point was PFS (by independent radiology review as per RECIST 
v1.1). mPFS was longer for pembrolizumab versus chemotherapy 
(10.3 versus 6.0 months) and disease progression or death was 
significantly better for pembrolizumab (HR 0.50, 95% CI 
0.37–0.68; p < 0.001). mOS has yet to be reached; however, the 
6-month OS for pembrolizumab versus chemotherapy was 80.2 
and 72.4%, respectively (HR 0.60, 95% CI 0.41–0.89; p = 0.005). 
Pembrolizumab had fewer TRAEs of any grade compared to 
chemotherapy (73.4 versus 90.0%), less grade 3–5 TRAEs (26.6 
versus 53.3%), and although had higher rates of immune-TRAEs 
(29.2 versus 4.7%) most were grade 1–2 severities and did not lead 
to any deaths. The second interim analysis by the data and safety 
monitoring committee determined that the benefit of pembroli-
zumab was large enough to warrant stopping the trial and offer 
the chemotherapy group pembrolizumab (34).
CheckMate 026 is a Phase 3, global, multicenter, open-label, 
1:1 randomized controlled trial comparing nivolumab 3  mg/kg 
every 2 weeks (n = 271) to the investigator’s choice of platinum-
based doublet chemotherapy (n = 270) in patients with Stage IV 
or recurrent squamous and non-squamous NSCLC who have 
not received previous systemic therapy for their disease and have 
PD-L1 expression on ≥1% of TCs. Nivolumab continued until 
disease progression or unacceptable toxicity. Treatment beyond 
progression was allowed. Platinum-doublet chemotherapy was 
given for up to six cycles and pemetrexed maintenance was allowed 
for non-squamous patients. Crossover from chemotherapy to 
nivolumab was allowed if PD occurred. The primary end point 
was PFS (by independent radiology review as per RECIST v1.1) 
in patients with PD-L1 expression ≥5%. Nivolumab did not 
improve mPFS compared to platinum-doublet among patients 
with PD-L1 expression ≥5%: 4.2 and 5.9  months, respectively 
(HR 1.15, 95% CI 0.91–1.45; p = 0.25). Surprisingly, in contrast 
to the Keynote 024 results, the PFS was not superior in the ≥50% 
PD-L1 cohort (PFS HR 1.07) in the subgroup analysis. The OS 
for the nivolumab and chemotherapy groups were similar with 
an mOS of 14.4 and 13.2 months, respectively (HR = 1.02, 95% 
CI 0.80–1.30). Nivolumab had less TRAEs of any grade and grade 
3–4 (71 and 18%), respectively, when compared to platinum-
doublet (92 and 51%) (35). Further knowledge on the use of first-
line nivolumab will be forthcoming from the ongoing CheckMate 
227 trial where the 1% PD-L1 positive arm includes patients 
randomized to combined immunotherapy with nivolumab and 
ipilimumab versus nivolumab alone versus chemotherapy in the 
first-line setting.
Combinations of immunotherapy and 
Chemotherapy
CheckMate 012 is a multi-cohort phase I clinical trial evaluating 
nivolumab as a single agent or in combination with chemo-
therapy, targeted therapy, or ipilimumab (a recombinant human 
IgG1 immunoglobulin that inhibits the CTLA-4 receptor). The 
data have been published from the platinum-doublet combi- 
nations (36). Three chemotherapy backbones were evaluated in 
56 patients: pemetrexed/cisplatin, gemcitabine/cisplatin, and 
paclitaxel/carboplatin. All three backbones were paired with 
nivolumab 10 mg/kg. An additional cohort of paclitaxel/carbo-
platin was accrued that was combined with nivolumab 5 mg/kg. 
Maintenance chemotherapy was not allowed but patients contin-
ued on maintenance of nivolumab until progression. The primary 
objective, ORR, was 47, 33, and 47% for the pemetrexed, gemcit-
abine and paclitaxel platinum combinations with the 10 mg/kg 
nivolumab dose, respectively; ORR for paclitaxel/carboplatin 
combination with 5 mg/kg nivolumab was 43%. Responses were 
seen irrespective of presence or absence of PD-L1 expression on 
the tumor. Two-year OS rates were 33, 25, and 27%, for the pem-
etrexed, gemcitabine and paclitaxel platinum combinations with 
the 10 mg/kg nivolumab dose, respectively. The 2-year OS rate for 
the paclitaxel/carboplatin combination with 5 mg/kg nivolumab 
was 62%. These objective response and 2-year survival rates for 
the nivolumab combinations were numerically increased over 
what we would have expected historically from platinum doublet. 
No dose-limiting toxicities occurred during the first two cycles 
of treatment. Forty-five percent of patients reported Grade 3–4 
TRAEs; 21% of patients discontinued all study therapy as a result 
of TRAEs.
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higher doses of ipilimumab (3  mg/kg) given every 3  weeks, 
similar to those used in melanoma, were not tolerable and had 
very high rates of TRAEs (49%) and treatment-related deaths in 
the NSCLC population (39). This prompted reassessment of dose 
and schedule. The results of nivolumab 3 mg/kg every 2 weeks 
in combination with ipilimumab 1 mg/kg every 6 or 12 weeks 
in 77 previously untreated metastatic NSCLC patients have been 
recently published (40). The ORR was 38 and 47% for the Q6 
and Q12 week ipilimumab cohorts, respectively. In patients 
with PD-L1 expression of 1% or greater, the ORR was 57% for 
both cohorts. OS at 1  year in the ipilimumab Q6 week cohort 
was 69%. The follow-up data were too immature at the time of 
publication to report the OS in the Q12 week cohort. Grade 
3–4 TRAEs occurred in 33 and 37% of patients in the Q6 and 
Q12 week cohorts, respectively. The majority of these TRAEs 
were auto-immune phenomena. No treatment-related deaths 
occurred. The results of the CheckMate 012 trial are the basis 
for the CheckMate 227 trial where PD-L1 positive (1%) patients 
are randomized to nivolumab 3  mg/kg every 2  weeks with 
ipilimumab 1  mg/kg every 6  weeks versus nivolumab 3  mg/kg 
every 2  weeks versus platinum doublet. The PD-L1 negative 
patients are randomized to nivolumab with ipilimumab at the 
dose and schedule above versus nivolumab with platinum-
doublet chemotherapy versus standard of care chemotherapy.
The phase Ib experience with the combination of durvalumab, 
an IgG1 antagonist antibody that binds PD-L1 and inhibits its 
function, with tremelimumab, a fully human IgG2 isotype that 
inhibits the CTLA-4 receptor, in NSCLC has recently been pub-
lished (41). In this dose-finding study, 102 patients were enrolled; 
94% of the patients had prior systemic therapy. The final toler- 
able dose was established as durvalumab 10 mg/kg and treme-
limumab 1  mg/kg both given every 4  weeks. Serious TRAEs 
occurred in 37 (36%) of 102 patients. Three treatment-related 
deaths occurred from suspected or confirmed autoimmunity 
(myasthenia gravis, pericardial effusion, and neuromuscular dis- 
order). In the final cohort of 26 patients treated at the tremeli-
mumab dose of 1 mg/kg, patients with both PD-L1 high (25%) 
as well as PD-L1 negative (0%) tumors had ORR 22 and 40%, 
respectively. Further work with this combination is being 
done in chemotherapy refractory (ARCTIC study) (42) and 
 chemotherapy-naïve (MYSTIC study) (43) NSCLC patients.
PD-L1 expression
Currently there are at least six monoclonal antibodies to assay 
PD-L1. The 28-8 antibody has been developed in conjunction 
with nivolumab. The 22C3 antibody has been developed with 
pembrolizumab. The 78-10 antibody has been developed with 
avelumab. Each of these three antibodies was developed initially 
on the DAKO autostainer platform. The SP142 antibody has 
been developed with atezolizumab. The SP263 antibody has been 
developed with durvalumab. Both of these antibodies were vali-
dated initially using the Ventana platform. Additional work has 
been published with the E1L3N antibody, which is commercially 
available and has been used in multiple laboratory-developed 
tests at numerous academic centers with both the DAKO and 
Ventana platforms. Work is now underway to cross compare the 
Keynote 021 is a multi-cohort Phase 1/2 randomized trial 
investigating the safety, tolerability, and efficacy of pembroli-
zumab in combination with platinum doublets, targeted therapy, 
and ipilimumab. The data were recently published from the 
randomized phase 2 cohort G which compared pemetrexed 
and carboplatin followed by pemetrexed maintenance with 
or without a maximum of 2  years of pembrolizumab in 123 
patients. Patients have Stage IIIb/IV non-squamous NSCLC and 
were stratified according to their PD-L1 TPS <1 versus ≥1%. 
Crossover from the chemotherapy group to the pembrolizumab 
group was permitted in the event of PD. The primary endpoint 
was ORR (by independent radiology review as per RECIST v1.1). 
Pembrolizumab combined with chemotherapy has a superior 
ORR versus chemotherapy alone (55 versus 29%, 95% CI 9–42%; 
p  =  0.0016). Subgroup analysis of PD-L1 stratification <1% 
versus ≥1% showed similar ORR for the pembrolizumab group 
(57 versus 54%, respectively) while the chemotherapy alone 
group showed a difference in ORR (13 versus 38%, respectively). 
Further stratification of PD-L1 to 1–49% and ≥50% had an 
ORR of 26 and 80%, respectively, for the pembrolizumab with 
chemotherapy group, versus 39 and 35%, respectively, for the 
chemotherapy alone group. Pembrolizumab with chemotherapy 
was able to achieve a superior mPFS versus chemotherapy 
alone (13.0 versus 8.9  months, HR 0.53, 95% CI 0.31–0.91; 
p  =  0.0102). mOS has not yet been met, and the 12-month 
OS has been 75% for those with pembrolizumab and chem- 
otherapy versus 72% for chemotherapy alone. Grade 3–5 TRAEs 
were similar between groups (39% in the pembrolizumab plus 
chemotherapy group versus 26% in the chemotherapy alone 
group), with similar treatment discontinuation rates (10% for the 
pembrolizumab arm compared to 13% for the chemotherapy only 
arm) and treatment-related deaths (one death in the pembroli-
zumab group secondary to sepsis, and two deaths in the chem- 
otherapy alone group due to sepsis and pancytopenia) (37).
immunotherapy Doublets
Based on the success of dual immunotherapy combinations in 
melanoma, PD-1 inhibitors have been combined with the CTLA-4 
inhibitor, ipilimumab. Cohort C from the Keynote 021 trial 
described above was presented at the ASCO Annual Meeting in 
2015 (38). This cohort was a dose finding and safety study. The 
initial doses of pembrolizumab were 10  mg/kg and doses of 1 
or 3  mg/kg of ipilimumab were planned. There were no safety 
signals at the 10 mg/kg dose of pembrolizumab with either dose 
of ipilimumab in the six patients treated, but, based on the emerg-
ing results from the CheckMate 012 trial, the final dose selected 
for further dose expansion was pembrolizumab 2  mg/kg and 
ipilimumab 1 mg/kg. Results were presented for the 15 patients 
treated at all dose levels. The ORR was 39% and the disease 
control rate was 83%. Immune TRAEs were identified in 33% of 
patients, half of whom had Grade 3 events (adrenal insufficiency 
and skin eruptions). This combination is being explored further 
in a randomized two cohort of Keynote 021 (cohort H).
The CheckMate 012 trial had several arms assessing the 
optimal dosing of nivolumab and ipilimumab in chemotherapy-
naïve patients with NSCLC. Initial dose combinations with 
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antibodies. Several studies have now been published including 
phase 1 of the BluePrint PD-L1 Assay Comparison Project (44). 
The results of this work consistently note that the 28-8, 22C3, 
and SP263 antibodies are comparable when staining tumor cells. 
The SP142 antibody has more variability when compared to the 
other three antibodies. In general, all four antibodies have greater 
variability when assaying ICs. Work is also underway to assess 
the reliability of some of the antibodies on alternative staining 
platforms. Recently, the Ventana platform has been shown to also 
be reliable for 22C3 analysis (45). While the FDA has approved 
many of these antibodies as either companion or complementary 
diagnostics, due to the high cost of these tests, globally, laboratory- 
developed assays for PD-L1 are likely to predominate. At this 
point, the authors recommend that a well-validated assay be 
used to determine the presence or absence of PD-L1 staining. 
The key to this is the requirement for rigorous validation metho- 
dology if a laboratory-developed assay is going to be used. This 
sentiment has been demonstrated in the recently presented 
Multi-center French Harmonization Project (46). The 22C3, 
28-8, SP263, and E1L3N antibodies were generally comparable. 
This study did show significant variability in the detection of PD- 
L1-positive tumor cells when laboratory-developed tests were 
used. The key is a thorough initial and ongoing validation process 
for laboratory-developed tests.
With that background, understanding the molecular determi-
nants of response to immunotherapies is a difficult clinical chal-
lenge. Presently, PD-L1 expression levels have shown a variable 
ability to predict response to checkpoint inhibition. CheckMate 
017 did not show any clear predictive benefit of PD-L1 analysis 
at the reported 1, 5, and 10% cut points for squamous histology 
patients. CheckMate 057 did show significant improvement in 
ORR, PFS, and OS with nivolumab for non-squamous patients 
expressing any level of PD-L1, but there is clear escalating benefit 
with increasing PD-L1 expression in the published 1, 5, and 10% 
cut points (47). The OAK study also showed that atezolizumab, 
when compared to docetaxel, produced OS benefit regardless 
of PD-L1 expression on either TC or IC, but again, increased 
magnitude of benefit is seen when patients with increasing 
PD-L1 expression are identified (33). The Keynote 010 trial only 
included PD-L1 positive patients, and although it does not 
offer information about the PD-L1-negative patients, there was 
increasing benefit when the patients with low expression (1–49%) 
are contrasted with the patients with high expression (≥50%) 
(31). Consistently in patients with non-squamous tumors who 
have progressed on platinum doublet, there is increased chance 
of benefit with increased PD-L1 expression. The struggle for clini-
cians is that the benefit in the PD-L1 low and/or negative groups 
is not zero, nor is it clinically insignificant, making use of PD-L1 
as a biomarker in the refractory setting a challenge.
There has been documented success when stratifying patients 
for PD-L1 using the 22C3 antibody at the 50% cut point. This 
cut point was clinically validated during the Keynote 010 phase 
I trial that showed both pembrolizumab at either 2 or 10 mg/kg 
dose significantly improved OS in patients with ≥50% PD-L1 
expression, which was numerically greater than the benefits seen 
in the low expressing cohort (48). Keynote 024 also demonstrated 
dramatic benefits of pembrolizumab in comparison to platinum-
doublet chemotherapy in previously untreated patients with 
PD-L1 expression ≥50%. This comes in contrast to what has been 
seen with the 28-8 antibody. The results of the CheckMate 026 
trial are perplexing. If the 22C3 and 28-8 antibodies select patients 
similarly, as is suggested by several recent publications including 
the initial publication of the BluePrint PD-L1 Assay Comparison 
Project, one would expect the patients treated with nivolumab 
who had ≥50% PD-L1 expression to do better with immu- 
notherapy than chemotherapy, but this was not demonstrated 
(44, 49). The CheckMate 026 study was not designed nor powered 
to look at this subgroup. Confirmatory information about the 
benefits of PD-L1 inhibition in the chemotherapy-naïve first-line 
setting is needed. The Keynote 042 trial is ongoing (50). This trial 
is similar to the CheckMate 026 trial where patients with ≥1% 
PD-L1 staining are eligible to enroll. Patients are stratified by 
PD-L1 expression using the 50% cut point and randomized to 
pembrolizumab versus standard platinum-doublet chemother-
apy. The high expressing group can then be used to confirm the 
Keynote 024 data. As mentioned earlier, the ongoing Checkmate 
227 trial has a nivolumab monotherapy arm for patients with ≥1% 
PD-L1 expression. Again, this trial was not designed to look 
specifically at the 50% PD-L1-positive group but may yield a 
signal as to whether there is benefit of nivolumab alone in the 
first-line setting.
Other Potential biomarkers
A multivariate exploratory analysis of baseline serum cytokines 
levels in 222 nivolumab-treated patients in either Checkmate 
017 or 063 trials was presented at the April 2016 ELCC (51). The 
effect of the cytokine set on OS was quantified by generating an 
SQ-cytoscore defined as “high” or “low” based on the median cut-
off. Those with a high SQ-cytoscore (n = 102) achieved an mOS of 
15.6 months, approximately three times longer than 5.3 months of 
those with a low SQ-cytoscore (n = 120) (HR 0.48, 95% CI 0.36–0.64; 
p < 0.0001), respectively. While clinical factors are not suitable to 
determine sensitivity to PD-1 inhibition and PD-L1 expression 
does not predict response in squamous-NSCLC, the SQ-cytoscore 
may serve as a predictive marker for anti-PD-1 therapy. Prospec- 
tive validation of these preliminary findings is required.
Due to tumor heterogeneity and the fluctuant infiltration of ICs 
into the tumor microenvironment (52), future biomarker inves-
tigations may look at other checkpoint molecules (53), TIIC (54), 
blood-based immune analyses (55), inflammatory gene signa-
tures (56), and mutational load (57). In two independent cohorts, 
whole-exome sequencing of patients with NSCLC treated with 
pembrolizumab found an improved ORR, PFS, and durability in 
patients with higher tumor non-synonymous mutational load. 
Mutation burden was also associated with DNA repair pathway 
mutations, larger neoantigen burden, and molecular smoking 
signature; each factor was also correlated with clinical efficacy 
(57). Mutational burden is largely a consequence of chronic 
exposure to mutagens, and hence non-smoking NSCLC patients 
tend to harbor fewer mutations (58). Future prospective studies 
will need to explore the role of smoking exposure to durability 
of response.
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Future work
Future trials will continue to explore the potential of combina-
tion therapy of PD-1 inhibition with chemotherapy, targeted 
therapy, or other immuno-oncology agents. Chemotherapy 
has been shown to increase PD-L1 expression on TCs (59, 60), 
in addition to possibly reducing the quantity and activity of 
suppressive ICs, inducing immunogenic cell death, activat-
ing and maturing dendritic cells, enhancing tumor antigen 
presentation, and increasing effector T-cell function (61). 
Beyond cytotoxic chemotherapy combinations, the PD-1 
inhibitors are being combined with targeted therapies such 
as the EGFR and ALK inhibitors. As listed above, there are 
numerous clinical trials currently investigating the potential 
of combination immunotherapy in NSCLC, of which the 
majority are investigating the combination of PD-1/PD-L1 
inhibition with CTLA-4 inhibition, but other novel checkpoint 
inhibitors are also entering phase I development. Studies are 
also investigating the role of PD-1 inhibition in the adjuvant 
setting in the ANVIL (nivolumab), PEARLS (pembrolizumab), 
IMpower010 (atezolizumab), and BR31 (durvalumab) trials as 
well as in locally advanced disease (PACIFIC). Beyond inves-
tigating immunotherapy in earlier stages of NSCLC, further 
work needs to be done to understand the mechanisms of 
resistance to this class of drugs. Loss-of-function mutations in 
the interferon-receptor-associated Janus kinase 1 (JAK1) and/
or Janus kinase 2 (JAK2) genes in melanoma and mismatch 
repair-deficient colon cancer have been implicated in acquired 
resistance, or possibly even primary resistance, to PD-1 
inhibition (62, 63). JAK1/2 is required for signaling through 
the interferon-γ receptor, a process required for TC PD-L1 
expression (9). Hence inactivating JAK1/2 mutations lead to 
loss of PD-L1 expression and lack of response to anti-PD-1/
L1 therapy. While this mechanism has yet to be studied in 
NSCLC, it warrants further exploration as a possible biomarker 
of resistance. This paper also noted changes in the folding and 
localization of major histocompatibility complex (MHC) 1 to 
the cell surface in patients who have developed resistance to 
PD-1/L1 checkpoint inhibition through mutations in the beta-
2-microglobulin gene. The presence of MHC on the surface of 
tumor cells is required for T-cell cytotoxicity and lack of pres-
ence of MHC on the surface will mitigate the effect of PD-1/L1 
checkpoint inhibition.
CONCLUSiON
Based on the data we have to date, in patients who have not 
received prior therapy for metastatic NSCLC, pembrolizumab 
could be offered as an alternative to platinum-doublet chemo-
therapy for those patients who express PD-L1 on ≥50% of their 
TCs based on the Keynote 024 trial. Confirmatory data will be 
forthcoming to support this single positive trial. In the refrac-
tory setting, nivolumab, pembrolizumab, and atezolizumab 
have all shown benefit in phase 3 clinical trials. Nivolumab is 
the only agent tested in a phase 3 trial with both known and 
unknown PD-L1 expression and demonstrated an OS benefit. 
Atezolizumab has shown a significant survival benefit in both 
the PD-L1 positive and negative patients (patients in this trial 
were required to have adequate tissue to document PD-L1 status). 
Pembrolizumab should only be given to patients who have known 
PD-L1 expression of at least 1%. We look forward to further phase 
3 randomized data of the immunotherapy combination strategies 
but for now this strategy should be reserved for clinical trials.
Anti-PD1 and PD-L1 in NSCLC treatment have durable 
response rates of approximately 20% that produce remarkable 
long-term survival. Toxicity is more favorable than chemotherapy, 
however, unique to immune checkpoint blockade are immune 
TREAs, of which the Grade 3–4 occurring in 5% of patients leads 
to treatment discontinuation. PD-L1 expression levels show a 
variable response to checkpoint inhibition, and at present they 
are not essential to guide therapy in the patients who have failed 
platinum doublet. In contrast, PD-L1 expression appears to be 
critical in assessing the potential benefit of PD-1 inhibition in the 
chemotherapy-naïve patient population. Determining predictive 
biomarkers to response is still undergoing further investigation. 
The rapidly evolving future of immunotherapy will continue 
with future studies investigating the potential of PD-1 inhibition 
in combination with chemotherapy, targeted therapy, or other 
immuno-oncology agents. We have entered a new era of lung 
cancer treatment.
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